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STUDY PROTOCOL

Open Access

Enhancing Cancer care of rural dwellers
through telehealth and engagement
(ENCORE): protocol to evaluate
effectiveness of a multi-level telehealthbased intervention to improve rural cancer
care delivery
Tuya Pal1,2, Pamela C. Hull3,4, Tatsuki Koyama1,5, Phillip Lammers6, Denise Martinez7, Jacob McArthy7,
Emma Schremp7, Ann Tezak2, Anne Washburn1, Jennifer G. Whisenant8 and Debra L. Friedman1,7*

Abstract
Background: Despite lower cancer incidence rates, cancer mortality is higher among rural compared to urban
dwellers. Patient, provider, and institutional level factors contribute to these disparities. The overarching objective of
this study is to leverage the multidisciplinary, multispecialty oncology team from an academic cancer center in
order to provide comprehensive cancer care at both the patient and provider levels in rural healthcare centers. Our
specific aims are to: 1) evaluate the clinical effectiveness of a multi-level telehealth-based intervention consisting of
provider access to molecular tumor board expertise along with patient access to a supportive care intervention to
improve cancer care delivery; and 2) identify the facilitators and barriers to future larger scale dissemination and
implementation of the multi-level intervention.
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Methods: Coordinated by a National Cancer Institute-designated comprehensive cancer center, this study will
include providers and patients across several clinics in two large healthcare systems serving rural communities.
Using a telehealth-based molecular tumor board, sequencing results are reviewed, predictive and prognostic
markers are discussed, and treatment plans are formulated between expert oncologists and rural providers.
Simultaneously, the rural patients will be randomized to receive an evidence-based 6-week self-management
supportive care program, Cancer Thriving and Surviving, versus an education attention control. Primary outcomes
will be provider uptake of the molecular tumor board recommendation and patient treatment adherence. A mixed
methods approach guided by the Consolidated Framework for Implementation Research that combines qualitative
key informant interviews and quantitative surveys will be collected from both the patient and provider in order to
identify facilitators and barriers to implementing the multi-level intervention.
Discussion: The proposed study will leverage information technology-enabled, team-based care delivery models in
order to deliver comprehensive, coordinated, and high-quality cancer care to rural and/or underserved populations.
Simultaneous attention to institutional, provider, and patient level barriers to quality care will afford the opportunity
for us to broadly share oncology expertise and develop dissemination and implementation strategies that will
enhance the cancer care delivered to patients residing within underserved rural communities.
Trial registration: Clinicaltrials.gov, NCT04758338. Registered 17 February 2021 – Retrospectively registered, http://
www.clinicaltrials.gov/
Keywords: Virtual molecular tumor board, Consolidated framework for implementation research (CFIR), Precision
medicine

Background
Rationale

Several studies have documented elevated cancer incidence and/or mortality in rural compared to urban communities [1–7], particularly pronounced in certain
regions of the United States (US), including the South
[8]. These differences have broad population health implications as almost 20% of Americans live in rural areas
[8, 9], but only 10% of physicians practice there [10].
Rural counties have some of the highest rates of poverty,
where residents are faced with limited availability to cancer treatment and supportive care services, transportation barriers, and financial issues [11–15]. Similarly,
challenges are faced by rural providers in delivering cancer care to their patients, with limited access to comprehensive care being the most important reason for
outcome disparities [16]. Moreover, the growing divide
in mortality between rural and urban dwellers [1, 5, 17–
19] highlights the need to evaluate multi-level interventions directed at providers and their patients to improve
outcomes.
Suggested strategies to enhance rural cancer care to alleviate issues associated with long travel distances comprise technology-based approaches to deliver remote
care delivery, inclusive of education and supportive care
[12]. Telehealth use in rural communities allows extension of care to wide geographic regions without patient
or provider travel. An Institute of Medicine report noted
that telehealth for rural hospitals drives volume and increases quality of care, while preserving low cost [20].

Telehealth has been successfully used for cancer screening, treatment, and supportive care [21–26], and been
expanded even further especially in the post COVID-19
era [27–31].
Provision of optimal cancer care delivery also requires
multispecialty and multidisciplinary input. Tumor
boards contribute to such input and provide evidenceand consensus-based data to optimize cancer treatment
and can be accessed virtually with interactive participation from large geographical regions [32–34]. With the
advent of next generation sequencing (NGS), the use of
tumor boards has expanded to meet new challenges
faced for physicians and patients, with respect to interpretation of results and translation to clinical interventions. To meet this need, we and others have developed
successful telehealth-based molecular tumor boards,
which enable community oncologists to present cases in
real time to an academic cancer center [35–37]. This is
particularly salient in rural communities, where there
are fewer oncologists and, subsequently, are faced with
the challenge of being well versed in the rapidlychanging molecular architecture of multiple tumor
types. Additionally, late stage disease at initial diagnosis
may be more common in rural patients [4] where molecular tumor diagnostics are more likely to direct targeted treatments. Therefore, telehealth-based molecular
tumor boards offer a mechanism to disseminate
evidence-based information from a National Cancer Institute (NCI)-comprehensive cancer center to its rural
catchment area.
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Supportive care self-management interventions

Self-management support is the systematic provision of
education and supportive care to increase the patients’
skills and confidence in managing their health problems
and is an integral component of the Chronic Care Model
[38–42]. Self-management interventions for cancer have
been developed with face-to-face, online and telehealth
models to minimize treatment-related symptoms and
distress, improve treatment adherence and psychosocial
wellbeing, and promote survival [39, 43–48]. The
Chronic Disease Self-Management Program (CDSMP) is
an evidence-based self-management intervention with
demonstrated efficacy across numerous chronic health
conditions with dissemination across the US, inclusive of
rural communities, and to 25 countries [40, 49–53]. The
CDSMP adaptation for cancer patients, Cancer Thriving
and Surviving (CTS), has demonstrated efficacy in improving patient-provider communication, energy, and
sleep, and reducing depression and stress-related
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problems [48, 54]. Yet access to such programs is limited
in rural communities with wide geographic areas. Therefore, evaluation of the effectiveness of the evidencebased CTS intervention delivered through telehealth
among rural patients is needed given its potential to improve patient outcomes.
Objectives and aims

The goal of this project is to assess improvement in delivery of quality cancer care using a multi-level telehealth
technology intervention tested at both the provider level
and the patient level in the rural catchment area of
Vanderbilt-Ingram Cancer Center (VICC), an NCIdesignated Comprehensive Cancer Center (Fig. 1). To
achieve this goal, this study has two specific aims:
Aim 1

Evaluate the clinical effectiveness of a multi-level
telehealth-based intervention for rural hospitals

Fig. 1 Location of Participating Vanderbilt Health Affiliate Network sites serving rural counties within the VICC Catchment area. This figure
illustrates the study’s catchment area throughout Tennessee and Mississippi, including a distinction between rural versus non-rural counties. Each
number represents the location of one of nine participating hospitals through the Vanderbilt Health Affiliated Network (VHAN), including seven
through the Baptist Memorial Health Care Corporation and two through Ballad Health. This figure was created by the authors specifically for this
clinical trial protocol
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consisting of provider access to tumor board expertise
that incorporates disease, patient, and molecular tumor
characteristics, together with patient access to a supportive care intervention to improve cancer care delivery.
Aim 2

Identify the facilitators and barriers to future larger scale
dissemination and implementation of the multi-level
intervention, designed to enhance the quality of rural
cancer care delivery.
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implementing the intervention (VICC and rural hospitals): structural characteristics (organization size, age,
maturity), the nature and quality of organization’s internal communications, general organizational culture,
implementation climate (intention for change, compatibility, relative priority, organizational incentives, goals/
feedback, learning climate), and the organization’s interventional readiness (leadership engagement, available resources for sustainability, access to information).

Methods/design
Conceptual framework for implementation

Overall study design

In order to identify potential barriers and facilitators that
may influence implementation and future dissemination
and to understand “what ‘works where and why’ across
multiple contexts” during and after implementation [55,
56], an implementation framework is helpful. The Consolidated Framework for Implementation Research
(CFIR), a meta-theoretical framework that delineates a
taxonomy of concepts to examine the process of implementation [55], was chosen for the current study as outlined in Fig. 2. The CFIR Outer Setting domain includes
factors outside of the implementing organizations such
as: patient needs and resources, the degree to which the
hospitals are networked with external organizations
(cosmopolitanism), peer competition with other hospitals, and external policies and incentives, such as
evidence-based expert practice guidelines and criteria for
treatment and reimbursement. The Inner Setting domain reflects characteristics of the organizations

This study will utilize information technology (IT)-enabled, team-based care delivery models to provide comprehensive, coordinated, high-quality cancer-related care
focused on rural populations. The study schema is presented in Fig. 3. We will evaluate the clinical effectiveness of a multi-level telehealth-based intervention in
hospitals that see large volumes of rural patients. The
intervention consists of provider access to tumor board
expertise that incorporates disease, patient, and molecular tumor characteristics along with patient access to a
supportive care intervention to improve cancer care delivery (Aim 1), and identification of facilitators and barriers to enable future larger scale dissemination and
implementation of the multi-level intervention that is
designed to enhance the quality of rural cancer care delivery (Aim 2). Simultaneous attention to institutional,
provider, and patient level barriers to quality care will
provide the opportunity for VICC, located in a region of

Fig. 2 Conceptual Framework: Implementation of Evidence-Based Cancer Care Delivery to Rural Populations via Telehealth. This figure illustrates
the conceptual framework for implementation of the multi-level telehealth intervention to bring evidence-based comprehensive cancer care to
patients in rural counties in Tennessee. The white blocks on the left indicate that we will evaluate the clinical effectiveness of delivering a multilevel telehealth intervention to rural hospitals to improve cancer care delivery, consisting of 1) provider-level access to tumor board expertise that
incorporates disease, patient, and molecular tumor characteristics, and 2) patient-level access to a supportive care intervention (Aim 1). The dark
gray block on the top right outlines the intervention outcomes. The gray blocks in the middle illustrate domains and subdomains of the CFIR
that we will examine during intervention delivery to identify barriers and facilitators to future larger scale dissemination and implementation of
the intervention (Aim 2)
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Fig. 3 Study schema. VICC, Vanderbilt-Ingram Cancer Center; HOPE, Hereditary and Oncologic Personalized Evaluation; CTS, Cancer Thriving and
Surviving intervention; EMR, electronic medical record

the country with some of the highest cancer mortality
rates [57], to broadly share oncology expertise, as well as
develop dissemination and implementation strategies to
remotely enhance patient care to underserved rural
communities.

Study setting

VICC is the sole NCI-designated Comprehensive Cancer
Center in Tennessee serving adult as well as pediatric cancer patients. The geographic placement of VICC, as well
as the regionally-renowned expertise in cancer care, presents a tremendous opportunity to develop strategies to
address regional disparities in rural cancer care, including
remote access to oncology expertise and supportive care.

Participating healthcare sites will include multiple
oncology practices (i.e., cancer clinics) within the
Vanderbilt Health Affiliated Network (VHAN), including the Baptist Memorial Health Care Corporation
and Ballad Health. Participants will include oncology
providers and patients at the aforementioned participating healthcare sites. The eligibility criteria are: 1)
At least 21 years of age or older and English speaking
with the ability to provide informed consent; 2) Oncology providers must treat patients within the designated VHAN oncology practices; 3) Patients with
newly diagnosed or relapsed disease that are patients
of the aforementioned oncology providers; and 4) Access to a reliable, video-capable device with internet
access.
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Data collection

This study will implement provider-level and patientlevel interventions using a mixed-methods approach.
The CFIR will be used to examine intervention delivery
to identify barriers and facilitators to future dissemination and implementation of the intervention [55, 56].
Both quantitative and qualitative data collection measures will be used, including baseline surveys before
intervention implementation surveys, qualitative interviews, and follow-up surveys after intervention. Provider
and patient recruitment along with the various surveys
that will be conducted per study phase (i.e., Enrollment
Phase, Tumor Board Phase, and Post-Intervention
Phase) are presented in Fig. 4.
Provider-level intervention and data collection

The provider will be asked to complete a baseline survey to
collect demographic information, including gender, age, race,
ethnicity, and number of years post fellowship training. In
addition to demographics, this survey will also assess the financial, emotional, and educational needs of rural cancer patients, and interest in expansion of telehealth services. To
measure relative advantage (CFIR intervention characteristic), providers will be asked to rate on a scale of 1–10 the
perceived need for remote access to the molecular tumor
board, perceived importance of educational and selfmanagement interventions for their patients, and interest in
participating in future research. An open-ended qualitative
item will ask for suggestions of needed support for the
intervention.
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At the tumor board, genomic, histologic, and clinical
data will be presented for further discussion and recommendations. The oncologist, with their patient, will decide if they will proceed with the recommendations, or
alternatively, start another treatment. Recommendations
and treatment changes will be collected.
Key informant interviews will be conducted with up to
10 participating oncologists at two points in time: 1)
early implementation phase (six months after intervention initiation); and 2) maintenance phase (two years
after initiation). The interview questions are adapted
from the existing CFIR Interview Guide [58], covering
the selected constructs under each of the five CFIR
major domain. Interviews will be conducted by telephone using a semi-structured interview guide and will
last about 20 min; all interviews will be audio recorded.
Patient-level intervention and data collection

If the patient expresses interest in the study, the provider will confirm eligibility then prompt them to
complete the informed consent. If reliable access to a
device with video and internet access is not available, a
device will be mailed to patient’s home after they enroll
and a data plan will be provided. These two resources
will come at no cost to the patient, and the device will
be returned at the conclusion of the study. Reasons for
lack of participation will be tracked as a potential barrier
to future dissemination.
Consented participants will be asked to complete a
baseline survey to collect demographic information,

Fig. 4 Recruitment and surveys conducted at the provider level and patient level per study phase. The action and particular survey that will be
completed by both the provider and patient for the Enrollment Phase, Tumor Board Phase, and Post-Intervention Phase is illustrated. MTB,
molecular tumor board; CTS, Cancer Thriving and Surviving
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including race, ethnicity, highest level of education, annual household income, and zip code; age and gender
will be extracted from the medical record. Participants
will then be randomized (1:1) into the CTS Program
Arm or Education Attention Control Arm (Fig. 3). Participants randomized to CTS will have a 6-week intervention delivered via telehealth using the VUMC
telehealth services (Table 1).
Key informant interviews will be conducted with up to
25–30 patient participants in the CTS arm of the study
approximately 6 months after the last session of the intervention. An index combining all of the patient-level outcome variables at pre-intervention and post-intervention
will be created to calculate the pre-post difference with
positive values indicating an improvement and negative
values indicating a decrease. The interview questions are
adapted from the existing CFIR Interview Guide [58], covering the selected constructs under each of the five CFIR
major domain. Interviews will be conducted by telephone
using a semi-structured interview guide and lasting about
20 min; all interviews will be audio recorded.
Participants in the Education Attention Control Arm
will receive publicly available online educational materials compiled in a password protected website that
broadly covers the same topics as the CTS syllabus and
enables the study team to track how the participant navigates through these educational materials. All materials
are drawn from preexisting public domains such as the
National Institutes of Health, NCI, and the American
Society of Clinical Oncology.
Data analysis

Data will be analyzed sequentially in three phases:
quantitative-qualitative-quantitative (i.e., baseline survey,
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interviews, and follow-up surveys). We will use connecting processes to combine both types of data, thus allowing one dataset to build upon another dataset in each
sequential phase.
Process evaluation data

Implementation penetration will be assessed as a ratio of
number of patients who participate in each group divided by total number of potential participants at each
recruitment site. The recruitment rate will be calculated
as the number of weeks required to recruit at least eight
participants in each arm of the patient-level component.
To address execution, three dimensions of intervention
fidelity for the CTS program will be measured. Adherence of the group facilitators to the CTS protocol will be
measured using an adapted Fidelity Checklist [59] completed by the facilitators to document completion of required activities. Exposure of patients to the intervention
will be measured using participation/attendance logs and
website analytics on usage of the online information.
Participant responsiveness will be measured as satisfaction with the intervention from the post surveys. These
measures will be combined into a fidelity score. Other
data collected will include patient cancer type and stage,
institution size, practice size, and number of rural counties with persistent poverty served and deprivation index,
as indicators of structural characteristics.
Qualitative data

Audio recordings will be transcribed with no identifiers.
Qualitative software (e.g., ATLAS.ti or RQDA) will be
used to code the transcripts using the CFIR Codebook
Template [58]. A thematic analysis method to identify
and analyze commonly recurring themes will be used

Table 1 Cancer Surviving and Thriving Syllabus
Week 1:
• Introduction to the Workshop
• Group Introductions
• The Mind/Body Connection/Distraction
• Fatigue Management and Getting Help
• Introduction to Action Plans

Week 4:
• Feedback
• Cancer and Body Changes
• Health Eating
• Communication Skills
• Problem-Solving
• Making an Action Plan

Week 2:
• Feedback/Problem Solving
• Dealing with Difficult Emotions
• Getting a Good Night’s Sleep
• Regaining Fitness During and after Cancer Treatment
• Making an Action Plan

Week 5:
• Feedback
• Endurance Exercise
• Making Decisions about Treatment and Complementary Therapies
• Maintaining a Healthy Weight
• Dealing with Depression
• Positive Thinking
• Making an Action Plan

Week 3:
• Feedback
• Managing Plan
• Living with Uncertainty
• Making Decisions
• Future Plans for Healthcare
• Making an Action Plan

Week 6:
• Feedback/Problem-Solving
• Cancer and Relationships
• Guided Imagery
• Working with Your Healthcare Professional
• Looking Back and Planning for the Future
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[60], then themes will be summarized for each group.
Open-ended qualitative responses from surveys will be
coded into categories based on emergent themes, then
merged with the quantitative data sets as categorical
variables.
Quantitative data and intervention outcomes

Survey data will primarily be summarized with descriptive statistics (i.e., frequencies/percentages for categorical
variables and means/standard deviations for continuous
variables) along with bivariate comparisons across sites
and between provider and patient data, where appropriate using chi-squared tests, t-tests, and analysis of
variance.
The primary outcomes will be provider uptake of the
VICC HOPE molecular tumor board treatment recommendation and patient treatment adherence. Secondary
outcomes include progression-free survival (PFS), patient
functional and psychosocial well-being, and patientprovider communication. Outcomes will be compared
between the CTS and attention control groups. Table 2
provides a list of the tools that will be utilized to measure these outcomes.
For the provider primary outcome, a logistic regression
model will be fit with the following patient-level,
provider-level, and institution-level variables as potential
effect modifiers. Patient-level includes: cancer type, race,
ethnicity, age and gender; provider-level includes: age,
years since completion of fellowship training, race, ethnicity, gender; and institution-level includes: institution
size (number of inpatient beds and outpatient infusion
chairs), practice size (oncologists, nurses, advanced practice providers) and number of rural counties with persistent poverty served. Note that the outcome will most
likely be correlated within the same provider, and to account for this correlation, we will use generalized estimating equations (GEE) with an independent weight
matrix. Because the CTS Program Arm will be delivered
to a group of 8 to 10 patients at a time, we will consider
this as a crossed random effect. The Education Attention
Control Arm will not have groups, and we will treat
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each individual as their own group to fit the model.
Institution-level data will be used as fixed effects.
The secondary endpoints will be analyzed similarly
using the regression approach taking into account the
potential clustering effect of the treatment delivery
group and practice. For a continuous outcome, mixedeffects model will be used; for PFS, we will use mixed effects Cox regression model to account for the intervention group clusters.
Sample size and power analysis

We expect to present 450 cases to the molecular tumor
board, and we expect 300 patients to be randomized at 1
to 1 to the two treatment groups. For the patient-level
intervention, we can detect treatment effect (difference
in binary outcome) if the true successful (adherence)
proportions are 75% (telehealth) and 60% (control) with
80% power while controlling type I error rate at 5%.

Discussion
Participation in this study will directly test the clinical
effectiveness of a telehealth implementation strategy for
disseminating genomic cancer information for optimal
patient care across diverse communities within and beyond the catchment area of VICC. This will allow iterative development of best practices for cancer care
delivery to rural communities. This study is testing a
novel multi-level intervention with simultaneous evaluation of provider and patient components to improve
cancer care among underserved individuals in rural
communities. A multi-level intervention to assess improvement in delivery of quality cancer care will be
tested: 1) at the provider level through access to an
existing telehealth-based molecular tumor board and
availability to disease-specific expertise at VICC; and 2)
the patient level through a telehealth-based supportive
care intervention.
Using the CFIR model, we chose a multi-level intervention that includes both provider and patient level
components. However, as such, it may be difficult to determine the relative contribution of each of the

Table 2 Assessment surveys that will be used to evaluate outcomes from the provider and patient
Name of Tool

Measurement

The Visual Analogue Scale [61]

Patients mark a line at the point along a continuum showing how much of each drug they have taken in the
past month

The Distress Thermometer [62]

Level of patient distress (0–10 scale) and problems contributing to it

The Functional Assessment of Cancer Health related quality of life in four primary domains: physical well-being, social/family well-being, emotional
Therapy [63]
well-being, and functional well-being
The MD Anderson Symptom
Inventory [64]

Thirteen common symptoms faced by cancer patients for severity and interference with aspects of daily life
on a 10-point numeric rating scale

The Communication Assessment Tool Patients rate communication with the physician on a 15-item instrument that employs a five-point response
[65]
scale
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components. To overcome this limitation, we have developed some analyses of each component for Aim 1
and will look across institutional, provider, and patient
levels for barriers and facilitators for future larger scale
implementation in Aim 2. In addition, there may be
cases with only an oncologist or patient participant.
While we don’t expect this to be a high number, discordant participation will reflect real world circumstances and inform future dissemination and
implementation strategies.
As with all telehealth services, this study could be challenged by technical difficulties. However, VICC has successfully brought telehealth into rural counties with low
broadband connectivity. This includes combined use of
computers, tablets and smart phones for the participants.
To date, we have had no issues with VICC telehealth across
a number of service lines and research projects. Additionally, through the Vanderbilt University Medical Center
(VUMC), an institutional infrastructure exists for healthcare providers to deliver telehealth-based services. This
existing VUMC telehealth infrastructure and software is
available for use in the proposed study and access to broadband and devices will be provided to participants if needed.
This will inform future scaling of this intervention.
Summary and impact

With the proposed multi-level remote intervention, we
will 1) improve comprehensive cancer care delivery to
patients residing in rural communities with persistent
poverty; 2) use telehealth to broaden the reach of our
NCI-designated comprehensive cancer center in these
communities; 3) disseminate evidence-based information
to rural oncology providers using a tumor board to share
expertise in molecular tumor analysis and interpretation;
4) provide guidance on cutting-edge therapies based on
patient, disease, and tumor characteristics; and 5) offer
an evidence-based self-management intervention to rural
patients. Furthermore, we will collect data for future dissemination and implementation of this intervention in
order to decrease disparities in rural cancer patients with
limited access to comprehensive care.
Abbreviations
CDSMP: Chronic Disease Self-Management Program; CFIR: Consolidated
Framework for Implementation Research; CTS: Cancer Thriving and Surviving;
GEE: Generalized estimating eqs.; IT: Information technology; NCI: National
Cancer Institute; NGS: Next generation sequencing; PFS: Progression-free
survival; US: United States; VHAN: Vanderbilt Health Affiliated Network;
VICC: Vanderbilt-Ingram Cancer Center; VUMC: Vanderbilt University Medical
Center
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